文献速递糖尿病

系统生物学衍生生物标志物预测2型糖尿病肾功能下降进展

Systems Biology-Derived Biomarkers to Predict Progression of Renal Function Decline in Type 2 Diabetes.
PubMed 文献 · Diabetes Care · 2017-01-11

研究基于系统生物学方法筛选出9种血清蛋白生物标志物,在1765例2型糖尿病合并慢性肾脏病(CKD)患者中验证其预测估算肾小球滤过率(eGFR)下降的能力。生物标志物联合临床风险因素可提高预测效能,在基线eGFR≥60和<60 mL/min/1.73 m²患者中调整R²分别达35%和64%。

要点

  • 9种血清蛋白生物标志物联合临床变量可提升2型糖尿病合并CKD患者肾功能下降的预测。
  • 基线eGFR≥60 mL/min/1.73 m²患者中,联合模型调整R²为35%。
  • 基线eGFR<60 mL/min/1.73 m²患者中,联合模型调整R²为64%。

核心结论

  • 系统生物学方法识别的小组血清蛋白生物标志物联合临床变量,可在广泛基线eGFR范围内增强2型糖尿病合并CKD患者肾功能下降的预测。

研究设计与样本

  • 利用公开组学数据构建糖尿病CKD分子过程模型,识别9种分子生物标志物,并在两项大型临床试验招募的1765例2型糖尿病合并CKD患者基线血清样本中测量。
  • 基于分子标志物、临床风险因素(包括基线eGFR和白蛋白尿)及两者组合预测eGFR下降,采用混合线性回归模型评估纵向数据。

主要发现

  • 基线eGFR≥60 mL/min/1.73 m²患者中,生物标志物解释的年eGFR下降变异调整R²为15%,临床预测因子为20%,联合后调整R²为35%。
  • 基线eGFR<60 mL/min/1.73 m²患者中,生物标志物解释的年eGFR下降变异调整R²为34%,临床预测因子为31%,联合后调整R²为64%。
  • 标志物模型校准分析显示显著偏离最佳校准(所有P<0.0001),但 largely irrelevant(校准-in-the-large:两组分别为-1.125和0.95;校准斜率分别为1.07和1.13)。

关键数值与推荐

  • 9种分子生物标志物:几丁质酶3样蛋白1、生长激素1、肝细胞生长因子、基质金属蛋白酶(MMP)2、MMP7、MMP8、MMP13、酪氨酸激酶和肿瘤坏死因子受体-1。
  • 基线eGFR≥60 mL/min/1.73 m²患者中,联合模型调整R²为35%;基线eGFR<60 mL/min/1.73 m²患者中为64%。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Chronic kidney disease (CKD) in diabetes has a complex molecular and likely multifaceted pathophysiology. We aimed to validate a panel of biomarkers identified using a systems biology approach to predict the individual decline of estimated glomerular filtration rate (eGFR) in a large group of patients with type 2 diabetes and CKD at various stages. RESEARCH DESIGN AND METHODS: We used publicly available "omics" data to develop a molecular process model of CKD in diabetes and identified a representative parsimonious set of nine molecular biomarkers: chitinase 3-like protein 1, growth hormone 1, hepatocyte growth factor, matrix metalloproteinase (MMP) 2, MMP7, MMP8, MMP13, tyrosine kinase, and tumor necrosis factor receptor-1. These biomarkers were measured in baseline serum samples from 1,765 patients recruited into two large clinical trials. eGFR decline was predicted based on molecular markers, clinical risk factors (including baseline eGFR and albuminuria), and both combined, and these predictions were evaluated using mixed linear regression models for longitudinal data. RESULTS: The variability of annual eGFR loss explained by the biomarkers, indicated by the adjusted R2 value, was 15% and 34% for patients with eGFR ≥60 and <60 mL/min/1.73 m2, respectively; variability explained by clinical predictors was 20% and 31%, respectively. A combination of molecular and clinical predictors increased the adjusted R2 to 35% and 64%, respectively. Calibration analysis of marker models showed significant (all P < 0.0001) but largely irrelevant deviations from optimal calibration (calibration-in-the-large: -1.125 and 0.95; calibration slopes: 1.07 and 1.13 in the two groups, respectively). CONCLUSIONS: A small set of serum protein biomarkers identified using a systems biology approach, combined with clinical variables, enhances the prediction of renal function loss over a wide range of baseline eGFR values in patients with type 2 diabetes and CKD.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Mayer G, Heerspink HJ, Aschauer C, et al. Systems Biology-Derived Biomarkers to Predict Progression of Renal Function Decline in Type 2 Diabetes. Diabetes Care. 2017. PMID: 28077457. doi:10.2337/dc16-2202

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。